A detailed history of Swiss National Bank transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 56,300 shares of KROS stock, worth $3.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,300
Previous 56,800 0.88%
Holding current value
$3.03 Million
Previous $2.6 Million 25.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$41.68 - $58.07 $20,840 - $29,035
-500 Reduced 0.88%
56,300 $3.27 Million
Q2 2024

Aug 08, 2024

BUY
$44.58 - $66.89 $307,602 - $461,541
6,900 Added 13.83%
56,800 $2.6 Million
Q1 2024

May 07, 2024

BUY
$41.26 - $70.48 $371,340 - $634,320
9,000 Added 22.0%
49,900 $3.3 Million
Q4 2023

Feb 06, 2024

SELL
$27.12 - $41.05 $127,464 - $192,935
-4,700 Reduced 10.31%
40,900 $1.63 Million
Q3 2023

Nov 08, 2023

BUY
$31.57 - $43.02 $66,297 - $90,342
2,100 Added 4.83%
45,600 $1.45 Million
Q2 2023

Aug 09, 2023

BUY
$37.26 - $51.01 $290,628 - $397,878
7,800 Added 21.85%
43,500 $1.75 Million
Q1 2023

May 10, 2023

SELL
$41.44 - $59.32 $66,304 - $94,912
-1,600 Reduced 4.29%
35,700 $1.52 Million
Q4 2022

Feb 08, 2023

BUY
$39.45 - $51.77 $122,295 - $160,487
3,100 Added 9.06%
37,300 $1.79 Million
Q3 2022

Nov 09, 2022

BUY
$27.8 - $40.12 $30,580 - $44,132
1,100 Added 3.32%
34,200 $1.29 Million
Q2 2022

Aug 09, 2022

BUY
$26.03 - $67.04 $70,281 - $181,008
2,700 Added 8.88%
33,100 $915,000
Q1 2022

May 09, 2022

BUY
$42.12 - $59.36 $96,876 - $136,528
2,300 Added 8.19%
30,400 $1.65 Million
Q2 2021

Aug 06, 2021

BUY
$42.4 - $70.11 $318,000 - $525,825
7,500 Added 36.41%
28,100 $1.19 Million
Q4 2020

Feb 05, 2021

BUY
$36.0 - $82.74 $741,600 - $1.7 Million
20,600 New
20,600 $1.45 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.39B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.